Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Goodwill & Intangibles: 2010-2024

Historic Goodwill & Intangibles for Ligand Pharmaceuticals (LGND) over the last 15 years, with Dec 2024 value amounting to $371.9 million.

  • Ligand Pharmaceuticals' Goodwill & Intangibles fell 11.86% to $335.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $335.1 million, marking a year-over-year decrease of 11.86%. This contributed to the annual value of $371.9 million for FY2024, which is 7.71% down from last year.
  • As of FY2024, Ligand Pharmaceuticals' Goodwill & Intangibles stood at $371.9 million, which was down 7.71% from $403.0 million recorded in FY2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Goodwill & Intangibles peaked at $785.0 million during FY2020, and registered a low of $342.5 million during FY2022.
  • Its 3-year average for Goodwill & Intangibles is $372.4 million, with a median of $371.9 million in 2024.
  • Its Goodwill & Intangibles has fluctuated over the past 5 years, first soared by 156.80% in 2020, then slumped by 52.01% in 2021.
  • Ligand Pharmaceuticals' Goodwill & Intangibles (Yearly) stood at $785.0 million in 2020, then tumbled by 52.01% to $376.7 million in 2021, then dropped by 9.09% to $342.5 million in 2022, then grew by 17.67% to $403.0 million in 2023, then dropped by 7.71% to $371.9 million in 2024.